Data / Form D filings / NewcelX Ltd.
NewcelX Ltd.: Form D filings
NewcelX Ltd., a biotechnology company in Kloten, Switzerland, filed 10 Form D notices with the SEC between 2022 and 2026. The latest, on August 24, 2026, reports $2.9 million sold of a $2.9 million offering to 5 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- HOHSTRASSE 1, Kloten, Switzerland, 8302
- Phone
- 41 44 512 21 50
- Industry
- Biotechnology
- Entity type
- Other
- Incorporated in
- Switzerland
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1783036
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 24, 2026 | New notice | $2,940,234 | $2,940,234 | 5 | Jul 3, 2026 | sec.gov | |
| May 13, 2026 | New notice | $3,428,989 | $3,428,989 | 4 | Apr 27, 2026 | sec.gov | |
| Jul 10, 2025 | New notice | $1,000,000 | $1,000,000 | 3 | Jun 27, 2025 | sec.gov | |
| Apr 14, 2025 | New notice | $2,000,000 | $2,000,000 | 3 | Mar 28, 2025 | sec.gov | |
| Jan 22, 2025 | New notice | $499,999 | $499,999 | 1 | Jan 7, 2025 | sec.gov | |
| Oct 21, 2024 | New notice | $7,200,000 | $7,200,000 | 6 | Oct 11, 2024 | sec.gov | |
| Jul 15, 2024 | New notice | $786,660 | $786,660 | 2 | Jun 28, 2024 | sec.gov | |
| Apr 3, 2024 | New notice | $1,750,000 | $1,750,000 | 2 | Mar 20, 2024 | sec.gov | |
| Dec 21, 2022 | New notice | $30,000,000 | $10,000,000 | $20,000,000 | 4 | Dec 13, 2022 | sec.gov |
| Oct 14, 2022 | New notice | $4,000,000 | $4,000,000 | 5 | Oct 7, 2022 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Ronen Twito | Executive Officer, Director | Executive Chairman and Chief Executive Officer |
| Michel Revel | Executive Officer, Director | |
| Kfir Molakandov | Executive Officer | |
| Omri Hagai | Executive Officer | Chief Financial Officer |
| Alexander C. Zwyer | Executive Officer, Director | |
| Olivier Samuel | Director | |
| Eran Iohan | Director | |
| Liora Oren | Director | |
| Tamar Galili | Director |
Every Form D from the week of Aug 24, 2026 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what NewcelX Ltd. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.